Skip to main content
Contact Us
Subscribe
E-Edition
66°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mink Therapeutics Inc
(NQ:
INKT
)
0.6800
+0.0020 (+0.29%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mink Therapeutics Inc
< Previous
1
2
Next >
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
November 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
November 11, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
November 07, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
October 31, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
October 08, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
October 04, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
September 03, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Reports Second Quarter 2024 Results and Business Update
August 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
August 01, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
July 31, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 05, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
May 22, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Reports First Quarter 2024 Results
May 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
May 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
April 30, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
April 08, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Reports Fourth Quarter and Year-End 2023 Results
March 21, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
March 07, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
March 06, 2024
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
From
MiNK Therapeutics
Via
GlobeNewswire
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
February 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
February 06, 2024
Treatment with agenT-797 Showed Improved Survival in Severe Respiratory Distress
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
January 30, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
December 20, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2023 Results
November 09, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
November 03, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
October 30, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
September 27, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Participate in September Investor Conferences
August 24, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Second Quarter 2023 Results
August 10, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
July 28, 2023
From
MiNK Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.